Home>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>(S)-10-Hydroxycamptothecin

(S)-10-Hydroxycamptothecin Sale

(Synonyms: 10-羟基喜树碱; 10-HCPT; 10-Hydroxycamptothecin) 目录号 : GC10098

A DNA topoisomerase I inhibitor

(S)-10-Hydroxycamptothecin Chemical Structure

Cas No.:19685-09-7

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥420.00
现货
25mg
¥294.00
现货
100mg
¥630.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Cell experiment [1]:

Cell lines

Colo 205 cells

Preparation method

Soluble in DMSO > 6.275mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

5, 10, 15, 20nM for 24, 48, 72, 96, 120hr

Applications

10-Hydroxycamptothecin inhibited the cell growth and reduced the cell viability of human colon cancer cell line Colo 205. The agent disturbed the cell cycle distribution which dramatically induced the increase of cell population in the G2/M phase and a decrease in the G0/G1 phase.

Animal experiment [2]:

Animal models

BALB/c-nu mice with Colo 205 cells xenograft tumor

Dosage form

Dissolved in propylene glycol; 1, 2.5, 5, 7.5 mg/kg per two or four days for 25days; oral administration

Application

The results of this study suggested that a relatively low dose of 10-Hydroxycamptothecin was able to inhibit the growth of colon cancer, with no acute toxicity observed.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Ping YH1, Lee HC, et al, Anticancer effects of low-dose 10-hydroxycamptothecin in human colon cancer. Oncol Rep. 2006 May;15(5):1273-9.

产品描述

IC50: 0.31 μM

10-Hydroxycamptothecin is a dose-dependent growth inhibitor of human microvascular endothelial cells (HMEC), and significantly inhibits the migration of HMEC with IC50 of 0.63 μM, resulting in a dose-dependent inhibition of tube formation with IC50 of 0.96 μM [1,2].

An antiangiogenic strategy may be effective as an anticancer therapy, because the growth and metastasis of solid tumors depend on the development of an adequate blood supply via angiogenesis [1,2].

In vitro: The proliferation of human microvascular endothelial cells (HMEC) and seven human tumor cell lines were detected by SRB assay, resulting in study the antiangiogenic potential of 10-hydroxycamptothecin (HCPT), ,and the endothelial cell migration and tube formation were assessed using two in vitro model systems[2].

In vivo: Using a modification of the chick embryo chorioallantoic membrane (CAM) assay defines inhibition of angiogenesis in vivo. Morphological assessment of apoptosis was performed by fluorescence microscope. HCPT 0.313-5 μmol/L treatment was in a dose-dependent inhibition of proliferation, migration and tube formation in HMEC cells, and HCPT 6.25-25 nmol/egg prevented angiogenesis in CAM assay. HCPT 1.25-5 μmol/L induced typical morphological changes of apoptosis (including condensed chromatin, nuclear fragmentation, and reduction in volume in HMEC cells). HCPT significantly blocked angiogenesis both in vitro and in vivo at relatively low concentrations, and this effect was connected with induction of apoptosis in HMEC cells. These results taken collectively reveal that HCPT may be a potential for antiangiogenetic and cytotoxic drug and further investigationis warranted [2,3].

Clinical trial: So far, no clinical study has been conducted.

References:
[1] Vladu B, Woynarowski JM, Manikumar G, Wani MC, Wall ME, Von Hoff DD, Wadkins RM.  7- and 10-substituted camptothecins: dependence of topoisomerase I-DNA cleavable complex formation and stability on the 7- and 10-substituents. Mol Pharmacol. 2000 Feb;57(2):243-51.
[2] Xiao D, Tan W, Li M, Ding J.  Antiangiogenic potential of 10-hydroxycamptothecin. Life Sci. 2001 Aug 24;69(14):1619-28.
[3] Ping YH, Lee HC, Lee JY, Wu PH, Ho LK, Chi CW, Lu MF, Wang JJ.  Anticancer effects of low-dose 10-hydroxycamptothecin in human colon cancer. Oncol Rep. 2006 May;15(5):1273-9.

Chemical Properties

Cas No. 19685-09-7 SDF
别名 10-羟基喜树碱; 10-HCPT; 10-Hydroxycamptothecin
化学名 (S)-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
Canonical SMILES CC[C@]1(O)C(C=C2C3=C(CN2C4=O)C=C5C=C(O)C=CC5=N3)=C4COC1=O
分子式 C20H16N2O5 分子量 364.35
溶解度 ≥ 23.8mg/mL in DMSO with gentle warming 储存条件 4°C, protect from light
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.7446 mL 13.7231 mL 27.4461 mL
5 mM 0.5489 mL 2.7446 mL 5.4892 mL
10 mM 0.2745 mL 1.3723 mL 2.7446 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置